Attendee search 

“AdeTherapeutics’ approach has potential to become standard of care,” says Dr. Greenberg, Vice Chair Obs & Gyn at Brigham and Women’s Hospital and Associate Professor at Harvard Medical School.

Our platform technology which KOL’s have pointed out as a game changer in the area of preventing post operative fibrosis, is poised to create significant value.  The pipeline contains a phase II drug for prevention of post operative fibrosis following pelvic and abdominal surgeries, med devices (collaboration with DSM Biomedical) for spinal surgery and additional opportunities in orthopedics.  

The Company has built a world class team, utilized a capital efficient, highly targeted and focused approach and brought on the necessary strategic partners to bring first-in-class products to the market and establish standard of care for millions of surgeries worldwide.Key value propositions:

•             useful in more procedures than current medical devices

•             significant higher efficacy vs market comparators

•             attractive safety profile & accelerated regulatory pathway

Key Milestones achieved:

• Phase II trial started
• Key markets patents issued: USA, EU, Japan
• Efficacy shown in different tissues areas
• Two peer reviewed publications in 2014

Deton is developing a novel non-invasive simple-to-use sample collection device for tuberculosis (TB) patients who are unable to provide a sample.

Proper diagnosis is essential to effectively treat the more than 9million new cases of TB every year. Typically, a sputum sample is collected to run the diagnostic test. However, in 22% of adults and in all children patients, sputum is impossible to collect. These patients have to rely on inadequate alternative collection methods that are invasive, high-cost, and resource-intensive. With our device, patients can now provide a sample even in low-resource setting and find out their TB status. Deton will enable 26M samples to be tested every year.

After promising clinical data, Deton is now raising $1.6M to build an ISO 13485 disposable product and to obtain pivotal clinical validation. Discussions with multiple potential diagnostic partners and first feedback from experts at World Health Organization show significant interest in adopting the device once effective validation has been completed. 

Headquartered in the greater Iowa City area, Corvida Medical innovates intelligent technologies that are designed to represent the next generation of safe handling of hazardous drugs and excellence in design.  We address the problems inherent in current methods and develop smarter, simpler solutions to improve safety, productivity and quality for providers and patients. Our first technology, a novel new Closed System Transfer Device – the Halo™ — will be available in 2015.

ORIG3N is a biotech company based in Boston, MA. The scientific mission is to deliver a disease-modeling platform targeting rare genetically inherited diseases. By advancing screening projects using iPSC-derived differentiated cells and rapidly delivering the resulting data to inform therapeutic decisions, ORIG3N will replace trial & error guess work of treating disease and enable longer, healthier lives. 

Headquartered in the greater Iowa City area, Corvida Medical innovates intelligent technologies that are designed to represent the next generation of safe handling of hazardous drugs and excellence in design.  We address the problems inherent in current methods and develop smarter, simpler solutions to improve safety, productivity and quality for providers and patients. Our first technology, a novel new Closed System Transfer Device – the Halo™ — will be available in 2015.

DELSIA is a "venture philanthropy" investment affilate of the research and advocacy foundation Autism Speaks. Our purpose is to transform lives by catalyzing the development and availability of innovative products.

DELSIA is a non-dilutive funding vehicle with the goal of improving outcomes for individuals with autism spectrum disorder (ASD). DELSIA aims to do this by enabling the translation of scientific breakthroughs and technological advances into products that improve health and quality of life for individuals with ASD and their families. 

Who and what do we invest in? DELSIA partners with for-profit companies to fund development activities necessary for delivering products that address the diverse unmet medical, behavioral health and quality of life needs of the autism community.

DELSIA accepts funding proposals from for-profit entities that include, but are not limited to:

• Entrepreneurs, start-up and small companies

• Life sciences, biotechnology and pharmaceutical companies

• Software, computer and electronic technology companies

RCT Ventures invests in early-stage life science companies including medical devices, drug discovery platforms, and research tools.